About the Company:
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enable it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities.
QoQ & YoY Performance:
World’s fourth specialty generic pharmaceutical company and India's top pharmaceutical company has declared the results for the second quarter of financial year ending March 2020.
QoQ Performance: Consolidated Net revenue of the company recorded to Rs.8123.35 crores, down by 3.00% in the September quarter of FY20. Total expenditure (excluding interest and depreciation expenses) are Rs.6333.61million, is fell by 0.71%. EBITDA numbers decreased by 9.87%.
- YoY Performance: The Company has reported a 17.09% increase in sales/revenue while expenditure (excluding interest and depreciation expenses) of the company have witnessed an uptake by 17.75%. EBITDA numbers surged by 5.75%.
- Profitability of the company: Net profits of the company resulted in gain of Rs.1064.09 crore, fell by 23.31% QoQ and surged by 494.69% YoY.
As per Lokesh Sethia, SEBI Registered Research Analyst, the stock was closed at Rs.442 per share in today’s trading session. The Company reported good profit margins. So, we are recommending buy the stock for the target price of 545.